miRNA-148a and miRNA-30c expressions as potential biomarkers in breast cancer patients

Breast cancer is an extensively identified malignant tumor and is a prime cause of cancer mortalities in females. It has been shown that alteration of miRNAs expression (up or down regulation) can affect the initiation and progression of many malignancies. We aimed to evaluate the role of circulatin...

Full description

Saved in:
Bibliographic Details
Published inBiochemistry and biophysics reports Vol. 27; p. 101060
Main Authors Elhelbawy, Nesreen G., Zaid, Ibrahim F., Khalifa, Aya A., Gohar, Suzy F., Fouda, Eman A.
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 01.09.2021
Elsevier
Subjects
Breast cancer
miRNA-148a
miRNA-30c
miRNA-148a
miRNA-30c
Breast cancer
Online AccessGet full text

Cover

Abstract Breast cancer is an extensively identified malignant tumor and is a prime cause of cancer mortalities in females. It has been shown that alteration of miRNAs expression (up or down regulation) can affect the initiation and progression of many malignancies. We aimed to evaluate the role of circulating miRNA-148a and miRNA-30c in female patients with breast cancer and estimate their usage as potential biomarkers in the diagnosis, prognosis and survival of breast cancer. This study included 75 breast cancer female patients.They were compared with 55 apparently healthy female subjects. miRNAs expression analysis was assessed via real-time PCR. To discriminate breast cancer patients from controls, miR-30c showed the best performance at a cut off value of ≤20.6 (AUC = 0.998, 97.33% sensitivity, 96.36% specificity, p < 0.001), followed by miR-148a (AUC = 0.995, 94.67% sensitivity, 90.91% specificity, p < 0.001 at a cut off value of ≤0.1), CA 15-3 (AUC = 0.930, 88.0% sensitivity, 81.82% specificity, p < 0.001 at a cut off value of >21.3), and finally CEA (AUC = 0.751, 70.67% sensitivity, 63.64% specificity, p < 0.001 at a cut off value of >2.5). miRNA-148a and miRNA-30c expressions were down regulated in female patients with breast cancer and might be considered as potential blood biomarkers. Both also might have rule in disease treatment and selection of therapeutic targets. Future studies are needed to improve their role in predicting response to treatment and prognosis. •miRNA-148a and miRNA-30c expressions were down regulated in female patients with breast cancer.•Lower levels of miR-148a were associated with lower overall survival and poor progression free survival.•Decreased level of miR-30c was not related to overall survival but it was associated with poor progression free survival.•In breast cancer patients, the expression level of miR-148a was positively correlated with miR-30c.
AbstractList Background: Breast cancer is an extensively identified malignant tumor and is a prime cause of cancer mortalities in females. It has been shown that alteration of miRNAs expression (up or down regulation) can affect the initiation and progression of many malignancies. We aimed to evaluate the role of circulating miRNA-148a and miRNA-30c in female patients with breast cancer and estimate their usage as potential biomarkers in the diagnosis, prognosis and survival of breast cancer. Methods: This study included 75 breast cancer female patients.They were compared with 55 apparently healthy female subjects. miRNAs expression analysis was assessed via real-time PCR. Results: To discriminate breast cancer patients from controls, miR-30c showed the best performance at a cut off value of ≤20.6 (AUC = 0.998, 97.33% sensitivity, 96.36% specificity, p < 0.001), followed by miR-148a (AUC = 0.995, 94.67% sensitivity, 90.91% specificity, p < 0.001 at a cut off value of ≤0.1), CA 15-3 (AUC = 0.930, 88.0% sensitivity, 81.82% specificity, p < 0.001 at a cut off value of >21.3), and finally CEA (AUC = 0.751, 70.67% sensitivity, 63.64% specificity, p < 0.001 at a cut off value of >2.5). Conclusion: miRNA-148a and miRNA-30c expressions were down regulated in female patients with breast cancer and might be considered as potential blood biomarkers. Both also might have rule in disease treatment and selection of therapeutic targets. Future studies are needed to improve their role in predicting response to treatment and prognosis.
• miRNA-148a and miRNA-30c expressions were down regulated in female patients with breast cancer. • Lower levels of miR-148a were associated with lower overall survival and poor progression free survival. • Decreased level of miR-30c was not related to overall survival but it was associated with poor progression free survival. • In breast cancer patients, the expression level of miR-148a was positively correlated with miR-30c.
Breast cancer is an extensively identified malignant tumor and is a prime cause of cancer mortalities in females. It has been shown that alteration of miRNAs expression (up or down regulation) can affect the initiation and progression of many malignancies. We aimed to evaluate the role of circulating miRNA-148a and miRNA-30c in female patients with breast cancer and estimate their usage as potential biomarkers in the diagnosis, prognosis and survival of breast cancer. This study included 75 breast cancer female patients.They were compared with 55 apparently healthy female subjects. miRNAs expression analysis was assessed via real-time PCR. To discriminate breast cancer patients from controls, miR-30c showed the best performance at a cut off value of ≤20.6 (AUC = 0.998, 97.33% sensitivity, 96.36% specificity, p < 0.001), followed by miR-148a (AUC = 0.995, 94.67% sensitivity, 90.91% specificity, p < 0.001 at a cut off value of ≤0.1), CA 15-3 (AUC = 0.930, 88.0% sensitivity, 81.82% specificity, p < 0.001 at a cut off value of >21.3), and finally CEA (AUC = 0.751, 70.67% sensitivity, 63.64% specificity, p < 0.001 at a cut off value of >2.5). miRNA-148a and miRNA-30c expressions were down regulated in female patients with breast cancer and might be considered as potential blood biomarkers. Both also might have rule in disease treatment and selection of therapeutic targets. Future studies are needed to improve their role in predicting response to treatment and prognosis.
Breast cancer is an extensively identified malignant tumor and is a prime cause of cancer mortalities in females. It has been shown that alteration of miRNAs expression (up or down regulation) can affect the initiation and progression of many malignancies. We aimed to evaluate the role of circulating miRNA-148a and miRNA-30c in female patients with breast cancer and estimate their usage as potential biomarkers in the diagnosis, prognosis and survival of breast cancer. This study included 75 breast cancer female patients.They were compared with 55 apparently healthy female subjects. miRNAs expression analysis was assessed via real-time PCR. To discriminate breast cancer patients from controls, miR-30c showed the best performance at a cut off value of ≤20.6 (AUC = 0.998, 97.33% sensitivity, 96.36% specificity, p < 0.001), followed by miR-148a (AUC = 0.995, 94.67% sensitivity, 90.91% specificity, p < 0.001 at a cut off value of ≤0.1), CA 15-3 (AUC = 0.930, 88.0% sensitivity, 81.82% specificity, p < 0.001 at a cut off value of >21.3), and finally CEA (AUC = 0.751, 70.67% sensitivity, 63.64% specificity, p < 0.001 at a cut off value of >2.5). miRNA-148a and miRNA-30c expressions were down regulated in female patients with breast cancer and might be considered as potential blood biomarkers. Both also might have rule in disease treatment and selection of therapeutic targets. Future studies are needed to improve their role in predicting response to treatment and prognosis. •miRNA-148a and miRNA-30c expressions were down regulated in female patients with breast cancer.•Lower levels of miR-148a were associated with lower overall survival and poor progression free survival.•Decreased level of miR-30c was not related to overall survival but it was associated with poor progression free survival.•In breast cancer patients, the expression level of miR-148a was positively correlated with miR-30c.
BACKGROUNDBreast cancer is an extensively identified malignant tumor and is a prime cause of cancer mortalities in females. It has been shown that alteration of miRNAs expression (up or down regulation) can affect the initiation and progression of many malignancies. We aimed to evaluate the role of circulating miRNA-148a and miRNA-30c in female patients with breast cancer and estimate their usage as potential biomarkers in the diagnosis, prognosis and survival of breast cancer. METHODSThis study included 75 breast cancer female patients.They were compared with 55 apparently healthy female subjects. miRNAs expression analysis was assessed via real-time PCR. RESULTSTo discriminate breast cancer patients from controls, miR-30c showed the best performance at a cut off value of ≤20.6 (AUC = 0.998, 97.33% sensitivity, 96.36% specificity, p < 0.001), followed by miR-148a (AUC = 0.995, 94.67% sensitivity, 90.91% specificity, p < 0.001 at a cut off value of ≤0.1), CA 15-3 (AUC = 0.930, 88.0% sensitivity, 81.82% specificity, p < 0.001 at a cut off value of >21.3), and finally CEA (AUC = 0.751, 70.67% sensitivity, 63.64% specificity, p < 0.001 at a cut off value of >2.5). CONCLUSIONmiRNA-148a and miRNA-30c expressions were down regulated in female patients with breast cancer and might be considered as potential blood biomarkers. Both also might have rule in disease treatment and selection of therapeutic targets. Future studies are needed to improve their role in predicting response to treatment and prognosis.
ArticleNumber 101060
Author Zaid, Ibrahim F.
Elhelbawy, Nesreen G.
Fouda, Eman A.
Khalifa, Aya A.
Gohar, Suzy F.
Author_xml – sequence: 1
  givenname: Nesreen G.
  surname: Elhelbawy
  fullname: Elhelbawy, Nesreen G.
  email: nesreen.elhalbawi@med.menofia.edu.eg
  organization: Department of Biochemistry and Molecular Biology. Faculty of Medicine, Menoufia University, Shebin Elkom City, Egypt
– sequence: 2
  givenname: Ibrahim F.
  surname: Zaid
  fullname: Zaid, Ibrahim F.
  organization: Department of Organic Chemistry. Faculty of Science, Menoufia University, Shebin Elkom City, Egypt
– sequence: 3
  givenname: Aya A.
  surname: Khalifa
  fullname: Khalifa, Aya A.
  organization: Chemist. Faculty of Science, Menoufia University, Shebin Elkom City, Egypt
– sequence: 4
  givenname: Suzy F.
  surname: Gohar
  fullname: Gohar, Suzy F.
  organization: Department of Clinical Oncology and Nuclear Medicine. Faculty of Medicine, Menoufia University, Shebin Elkom City, Egypt
– sequence: 5
  givenname: Eman A.
  surname: Fouda
  fullname: Fouda, Eman A.
  organization: Department of Biochemistry. Faculty of Science, Menoufia University, Shebin Elkom City, Egypt
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34195390$$D View this record in MEDLINE/PubMed
BookMark eNp9kU1v1DAQhi1UREvpL0BCPnLZxR9xYh9AqioKlSqQUMXVmkwmxUs2Dna2Kv--3qZU7YWTv9555vW8r9nBGEdi7K0Uaylk_WGzbttE01oJJfc3ohYv2JGqhFkZK-zBk_0hO8l5I4SQRlmj6lfsUFfSGe3EEfu5DT--na5kZYHD2PHlqAVyup0S5RzimDlkPsWZxjnAwNsQt5B-U8o8jLy4gDxzhBEp8QnmUGT5DXvZw5Dp5GE9Zlfnn6_Ovq4uv3-5ODu9XKFRZl5ZbKCvixXZaNHpXmm5dwgtguzLlywKh8qhs9Q4VRWdos6IDnrboar1MbtYsF2EjZ9SKMb--gjB31_EdO0hzQEH8uh0RbrRpkdb1a4g2lYqkLKWtWlUX1ifFta0a7fUYflGguEZ9PnLGH7563jjrdKu0q4A3j8AUvyzozz7bchIwwAjxV32ylSNqWrbmCLVixRTzDlR_9hGCr_P12_8fb5-n69f8i1V7546fKz5l2YRfFwEVEZ-Eyj5jCUOpC4kwrkMJfy3wR3agre9
CitedBy_id crossref_primary_10_2139_ssrn_4141631
Cites_doi 10.1007/s11033-019-04727-5
10.1111/j.1365-2559.1991.tb00229.x
10.3892/or.2015.4502
10.1016/S0140-6736(11)61625-5
10.18632/oncotarget.7953
10.1038/ncomms2393
10.1038/nature02871
10.21037/gs-20-472
10.3389/fendo.2018.00402
10.1016/j.cancergen.2020.08.005
10.1016/j.lfs.2020.118256
10.1016/j.abst.2019.05.001
10.1007/s13277-015-4688-0
10.1073/pnas.0307323101
10.1007/s00280-019-04024-9
10.1038/nature10983
10.1007/s10585-014-9642-9
10.1016/j.biopha.2016.05.049
10.1007/s13277-015-3926-9
10.1097/01.SLA.0000059969.64262.87
10.1038/jhg.2016.89
10.1186/s12943-016-0532-4
10.1186/s13046-017-0564-7
10.1186/s13046-020-01649-0
10.1016/j.biopha.2018.10.114
10.1016/j.devcel.2009.06.016
10.1016/S1674-8301(11)60022-5
10.3390/ijms20194940
10.1016/j.molonc.2015.01.008
10.3322/caac.21654
10.7150/jca.38449
10.1097/CAD.0000000000000498
10.1007/s10549-010-0940-x
10.7150/ijms.49801
ContentType Journal Article
Copyright 2021 The Authors
2021 The Authors.
2021 The Authors 2021
Copyright_xml – notice: 2021 The Authors
– notice: 2021 The Authors.
– notice: 2021 The Authors 2021
DBID 6I.
AAFTH
NPM
AAYXX
CITATION
7X8
5PM
DOA
DOI 10.1016/j.bbrep.2021.101060
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
PubMed
CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
Directory of Open Access Journals
DatabaseTitle PubMed
CrossRef
MEDLINE - Academic
DatabaseTitleList

PubMed

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Chemistry
EISSN 2405-5808
EndPage 101060
ExternalDocumentID oai_doaj_org_article_c934e3735fc8469dafbb12a11616572f
10_1016_j_bbrep_2021_101060
34195390
S2405580821001540
Genre Journal Article
GroupedDBID 0R~
0SF
457
53G
5VS
6I.
AACTN
AAEDW
AAFTH
AAFWJ
AALRI
AAXUO
ABMAC
ACGFS
ADBBV
ADEZE
AEXQZ
AFPKN
AFTJW
AGHFR
AITUG
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
AOIJS
BCNDV
EBS
EJD
FDB
GROUPED_DOAJ
HYE
IPNFZ
KQ8
M~E
NCXOZ
O9-
OK1
RIG
ROL
RPM
SSZ
ADVLN
AFJKZ
AKRWK
NPM
AAYXX
CITATION
7X8
5PM
ID FETCH-LOGICAL-c525t-8c7af69531730d3f2318526abca1f0608c09c29c98e79245312ed50daf8dc263
IEDL.DBID RPM
ISSN 2405-5808
IngestDate Tue Oct 22 15:08:52 EDT 2024
Tue Sep 17 21:11:07 EDT 2024
Fri Oct 25 11:56:14 EDT 2024
Thu Sep 26 15:57:29 EDT 2024
Sat Sep 28 08:19:53 EDT 2024
Tue Jul 25 20:59:54 EDT 2023
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords miRNA-148a
miRNA-30c
Breast cancer
Language English
License This is an open access article under the CC BY-NC-ND license.
2021 The Authors.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c525t-8c7af69531730d3f2318526abca1f0608c09c29c98e79245312ed50daf8dc263
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8239439/
PMID 34195390
PQID 2547546875
PQPubID 23479
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_c934e3735fc8469dafbb12a11616572f
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8239439
proquest_miscellaneous_2547546875
crossref_primary_10_1016_j_bbrep_2021_101060
pubmed_primary_34195390
elsevier_sciencedirect_doi_10_1016_j_bbrep_2021_101060
PublicationCentury 2000
PublicationDate 2021-09-01
PublicationDateYYYYMMDD 2021-09-01
PublicationDate_xml – month: 09
  year: 2021
  text: 2021-09-01
  day: 01
PublicationDecade 2020
PublicationPlace Netherlands
PublicationPlace_xml – name: Netherlands
PublicationTitle Biochemistry and biophysics reports
PublicationTitleAlternate Biochem Biophys Rep
PublicationYear 2021
Publisher Elsevier B.V
Elsevier
Publisher_xml – name: Elsevier B.V
– name: Elsevier
References Jiang, He, Ma (bib12) 2016; 35
Yu, Li, Xu (bib15) 2011; 25
Shukla, Sharma, Ward (bib34) 2015; 9
Curtis, Shah, Chin (bib21) 2012; 486
Luo, Wang, Niu (bib6) 2017
Pei, Li, Qian (bib32) 2020; 9
Ko, Jin, Lee (bib17) 2018; 40
Rodríguez-González, Sieuwerts, Smid (bib18) 2011; 127
Ma, Xu, Xu, Jiang (bib39) 2016; 37
Saleh, Soliman, Habib (bib10) 2019
Ambros (bib4) 2004; 431
Calin, Sevignani, Dumitru (bib14) 2004; 101
Han, Jiang, Zhang (bib7) 2017
Lai, Chen, Wang (bib33) 2017; 36
Siegel, Miller, Fuchs, Jemal (bib1) 2021; 71
O'Brien, Hayder, Zayed, Peng (bib5) 2018; 9
Khalife, Skafi, Fayyad-Kazan, Badran (bib8) 2020; 246–247
Li, Ren, Shi (bib25) 2017; 28
Edge, Byrd, Compton (bib19) 2010
Xue, Chen, Gu (bib13) 2016; 37
Han, Cui, Liang, Su (bib16) 2020; 11
Turchinovich, Weiz, Langheinz, Burwinkel (bib24) 2011
Xu, Zhang, Jasper (bib28) 2016; 7
Fazilaty, Mehdipour (bib26) 2014; 31
MacDonald, Tamai, He (bib27) 2009; 17
Bhat, Majid, Hassan (bib37) 2019; 1
Kurozumi, Yamaguchi, Kurosumi (bib9) 2017; 62
Loh, Norman, Lai, Rahman, Alitheen, Osman (bib11) 2019; 20
Elston, Ellis (bib20) 1991; 19
Liang, Feng, Shim (bib31) 2020; 85
Gao, Ge, Sun (bib29) 2019; 109
Huang, Wen, Yu (bib30) 2020; 39
Gong, Wang, Gao, Wang (bib38) 2016; 83
Peto, Davies (bib2) 2012; 379
Saikia, Paul, Chakraborty (bib23) 2020; 259
Xu, Ren, Wang (bib22) 2016; 15
Jin, Wang, Oppong-Gyebi, Hu (bib36) 2020; 17
Singletary (bib3) 2003; 237
Bockhorn, Dalton, Nwachukwu (bib35) 2013; 4
Jiang (10.1016/j.bbrep.2021.101060_bib12) 2016; 35
Luo (10.1016/j.bbrep.2021.101060_bib6)
Jin (10.1016/j.bbrep.2021.101060_bib36) 2020; 17
Ko (10.1016/j.bbrep.2021.101060_bib17) 2018; 40
Liang (10.1016/j.bbrep.2021.101060_bib31) 2020; 85
Han (10.1016/j.bbrep.2021.101060_bib16) 2020; 11
Xu (10.1016/j.bbrep.2021.101060_bib28) 2016; 7
Ma (10.1016/j.bbrep.2021.101060_bib39) 2016; 37
Curtis (10.1016/j.bbrep.2021.101060_bib21) 2012; 486
Yu (10.1016/j.bbrep.2021.101060_bib15) 2011; 25
Lai (10.1016/j.bbrep.2021.101060_bib33) 2017; 36
Loh (10.1016/j.bbrep.2021.101060_bib11) 2019; 20
Peto (10.1016/j.bbrep.2021.101060_bib2) 2012; 379
Huang (10.1016/j.bbrep.2021.101060_bib30) 2020; 39
Khalife (10.1016/j.bbrep.2021.101060_bib8) 2020; 246–247
Pei (10.1016/j.bbrep.2021.101060_bib32) 2020; 9
Gong (10.1016/j.bbrep.2021.101060_bib38) 2016; 83
Gao (10.1016/j.bbrep.2021.101060_bib29) 2019; 109
Singletary (10.1016/j.bbrep.2021.101060_bib3) 2003; 237
Bockhorn (10.1016/j.bbrep.2021.101060_bib35) 2013; 4
Han (10.1016/j.bbrep.2021.101060_bib7) 2017
Elston (10.1016/j.bbrep.2021.101060_bib20) 1991; 19
Edge (10.1016/j.bbrep.2021.101060_bib19) 2010
Shukla (10.1016/j.bbrep.2021.101060_bib34) 2015; 9
Li (10.1016/j.bbrep.2021.101060_bib25) 2017; 28
Siegel (10.1016/j.bbrep.2021.101060_bib1) 2021; 71
Xue (10.1016/j.bbrep.2021.101060_bib13) 2016; 37
Bhat (10.1016/j.bbrep.2021.101060_bib37) 2019; 1
Calin (10.1016/j.bbrep.2021.101060_bib14) 2004; 101
Fazilaty (10.1016/j.bbrep.2021.101060_bib26) 2014; 31
MacDonald (10.1016/j.bbrep.2021.101060_bib27) 2009; 17
Kurozumi (10.1016/j.bbrep.2021.101060_bib9) 2017; 62
Saikia (10.1016/j.bbrep.2021.101060_bib23) 2020; 259
Ambros (10.1016/j.bbrep.2021.101060_bib4) 2004; 431
Saleh (10.1016/j.bbrep.2021.101060_bib10) 2019
Turchinovich (10.1016/j.bbrep.2021.101060_bib24)
O'Brien (10.1016/j.bbrep.2021.101060_bib5) 2018; 9
Xu (10.1016/j.bbrep.2021.101060_bib22) 2016; 15
Rodríguez-González (10.1016/j.bbrep.2021.101060_bib18) 2011; 127
References_xml – start-page: 55
  year: 2017
  end-page: 66
  ident: bib7
  article-title: A Novel Panel of Serum miR-21/miR-155/miR-365 as a Potential Diagnostic Biomarker for Breast Cancer
  contributor:
    fullname: Zhang
– volume: 71
  start-page: 7
  year: 2021
  end-page: 33
  ident: bib1
  article-title: Cancer Statistics, 2021
  publication-title: Ca - Cancer J. Clin.
  contributor:
    fullname: Jemal
– volume: 379
  start-page: 432
  year: 2012
  end-page: 444
  ident: bib2
  article-title: Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials
  publication-title: Lancet (London, England)
  contributor:
    fullname: Davies
– volume: 259
  year: 2020
  ident: bib23
  article-title: Role of microRNA in forming breast carcinoma
  publication-title: Life Sci.
  contributor:
    fullname: Chakraborty
– volume: 9
  start-page: 1106
  year: 2015
  end-page: 1119
  ident: bib34
  article-title: MicroRNA-30c-2-3p negatively regulates NF-κB signaling and cell cycle progression through downregulation of TRADD and CCNE1 in breast cancer
  publication-title: Mol Oncol
  contributor:
    fullname: Ward
– volume: 246–247
  start-page: 18
  year: 2020
  end-page: 40
  ident: bib8
  article-title: MicroRNAs in breast cancer: new maestros defining the melody
  publication-title: Cancer Genet
  contributor:
    fullname: Badran
– year: 2017
  ident: bib6
  article-title: Elevated microRNA - 125b levels predict a worse prognosis in HER2 - positive breast cancer patients
  contributor:
    fullname: Niu
– volume: 127
  start-page: 43
  year: 2011
  end-page: 51
  ident: bib18
  article-title: MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer
  publication-title: Breast Canc. Res. Treat.
  contributor:
    fullname: Smid
– volume: 83
  start-page: 58
  year: 2016
  end-page: 63
  ident: bib38
  article-title: Decreased expression of microRNA-148a predicts poor prognosis in ovarian cancer and associates with tumor growth and metastasis
  publication-title: Biomed. Pharmacother.
  contributor:
    fullname: Wang
– volume: 19
  start-page: 403
  year: 1991
  end-page: 410
  ident: bib20
  article-title: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐up
  publication-title: Histopathology
  contributor:
    fullname: Ellis
– volume: 17
  start-page: 9
  year: 2009
  end-page: 26
  ident: bib27
  article-title: Wnt/β-Catenin signaling: components, mechanisms, and diseases
  publication-title: Dev. Cell
  contributor:
    fullname: He
– volume: 25
  start-page: 170
  year: 2011
  end-page: 177
  ident: bib15
  article-title: MiR-148a inhibits angiogenesis by targeting ERBB3
  publication-title: J Biomed Res
  contributor:
    fullname: Xu
– volume: 7
  start-page: 20381
  year: 2016
  end-page: 20394
  ident: bib28
  article-title: MiR-148a functions to suppress metastasis and serves as a prognostic indicator in triple-negative breast cancer
  publication-title: Oncotarget
  contributor:
    fullname: Jasper
– volume: 35
  start-page: 1425
  year: 2016
  end-page: 1432
  ident: bib12
  article-title: MicroRNA-148a inhibits breast cancer migration and invasion by directly targeting WNT-1
  publication-title: Oncol. Rep.
  contributor:
    fullname: Ma
– volume: 101
  start-page: 2999
  year: 2004
  end-page: 3004
  ident: bib14
  article-title: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
  contributor:
    fullname: Dumitru
– volume: 9
  start-page: 747
  year: 2020
  end-page: 758
  ident: bib32
  article-title: Downregulation of microRNA-30c-5p was responsible for cell migration and tumor metastasis via COTL1-mediated microfilament arrangement in breast cancer
  publication-title: Gland Surg.
  contributor:
    fullname: Qian
– volume: 237
  start-page: 474
  year: 2003
  end-page: 482
  ident: bib3
  article-title: Rating the risk factors for breast cancer
  publication-title: Ann. Surg.
  contributor:
    fullname: Singletary
– volume: 4
  start-page: 1393
  year: 2013
  ident: bib35
  article-title: MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11
  publication-title: Nat. Commun.
  contributor:
    fullname: Nwachukwu
– volume: 109
  start-page: 1062
  year: 2019
  end-page: 1069
  ident: bib29
  article-title: Ailanthone exerts anticancer effect by up-regulating miR-148a expression in MDA-MB-231 breast cancer cells and inhibiting proliferation, migration and invasion
  publication-title: Biomed. Pharmacother.
  contributor:
    fullname: Sun
– volume: 1
  start-page: 1
  year: 2019
  end-page: 8
  ident: bib37
  article-title: MicroRNAs and its emerging role as breast cancer diagnostic marker- A review
  publication-title: Adv Biomark Sci Technol
  contributor:
    fullname: Hassan
– volume: 11
  start-page: 2593
  year: 2020
  end-page: 2601
  ident: bib16
  article-title: Role of MicroRNA-30c in cancer progression
  publication-title: J. Canc.
  contributor:
    fullname: Su
– volume: 37
  start-page: 7915
  year: 2016
  end-page: 7920
  ident: bib39
  article-title: MicroRNA-148a represents an independent prognostic marker in bladder cancer
  publication-title: Tumor Biol.
  contributor:
    fullname: Jiang
– volume: 431
  start-page: 350
  year: 2004
  end-page: 355
  ident: bib4
  article-title: The functions of animal microRNAs
  publication-title: Nature
  contributor:
    fullname: Ambros
– volume: 40
  start-page: 3752
  year: 2018
  end-page: 3762
  ident: bib17
  article-title: Radioresistant breast cancer cells exhibit increased resistance to chemotherapy and enhanced invasive properties due to cancer stem cells
  publication-title: Oncol. Rep.
  contributor:
    fullname: Lee
– year: 2011
  ident: bib24
  article-title: Characterization of extracellular circulating microRNA
  contributor:
    fullname: Burwinkel
– volume: 31
  start-page: 595
  year: 2014
  end-page: 612
  ident: bib26
  article-title: Genetics of breast cancer bone metastasis: a sequential multistep pattern
  publication-title: Clin. Exp. Metastasis
  contributor:
    fullname: Mehdipour
– volume: 39
  start-page: 150
  year: 2020
  ident: bib30
  article-title: MicroRNA-148a-3p inhibits progression of hepatocelluar carcimoma by repressing SMAD2 expression in an Ago2 dependent manner
  publication-title: J. Exp. Clin. Canc. Res.
  contributor:
    fullname: Yu
– volume: 9
  start-page: 402
  year: 2018
  ident: bib5
  article-title: Overview of MicroRNA biogenesis, mechanisms of actions, and circulation
  publication-title: Front. Endocrinol.
  contributor:
    fullname: Peng
– start-page: 347
  year: 2010
  end-page: 376
  ident: bib19
  article-title: Breast
  publication-title: AJCC Cancer Staging Manual
  contributor:
    fullname: Compton
– year: 2019
  ident: bib10
  article-title: Potential value of circulatory microRNA122 gene expression as a prognostic and metastatic prediction marker for breast cancer
  publication-title: Mol. Biol. Rep.
  contributor:
    fullname: Habib
– volume: 36
  year: 2017
  ident: bib33
  article-title: Collagen triple helix repeat containing-1 negatively regulated by microRNA-30c promotes cell proliferation and metastasis and indicates poor prognosis in breast cancer
  publication-title: J. Exp. Clin. Canc. Res.
  contributor:
    fullname: Wang
– volume: 15
  start-page: 52
  year: 2016
  ident: bib22
  article-title: ErbB2 and p38γ MAPK mediate alcohol-induced increase in breast cancer stem cells and metastasis
  publication-title: Mol. Canc.
  contributor:
    fullname: Wang
– volume: 20
  start-page: 4940
  year: 2019
  ident: bib11
  article-title: The regulatory role of MicroRNAs in breast cancer
  publication-title: Int. J. Mol. Sci.
  contributor:
    fullname: Osman
– volume: 486
  start-page: 346
  year: 2012
  end-page: 352
  ident: bib21
  article-title: The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
  publication-title: Nature
  contributor:
    fullname: Chin
– volume: 62
  start-page: 15
  year: 2017
  end-page: 24
  ident: bib9
  article-title: Recent trends in microRNA research into breast cancer with particular focus on the associations between microRNAs and intrinsic subtypes
  publication-title: J. Hum. Genet.
  contributor:
    fullname: Kurosumi
– volume: 17
  start-page: 2964
  year: 2020
  end-page: 2973
  ident: bib36
  article-title: Application of nanotechnology in cancer diagnosis and therapy - a mini-review
  publication-title: Int. J. Med. Sci.
  contributor:
    fullname: Hu
– volume: 37
  start-page: 1581
  year: 2016
  end-page: 1590
  ident: bib13
  article-title: MicroRNA-148a inhibits migration of breast cancer cells by targeting MMP-13
  publication-title: Tumor Biol.
  contributor:
    fullname: Gu
– volume: 28
  start-page: 588
  year: 2017
  end-page: 595
  ident: bib25
  article-title: MicroRNA-148a promotes apoptosis and suppresses growth of breast cancer cells by targeting B-cell lymphoma 2
  publication-title: Anti Canc. Drugs
  contributor:
    fullname: Shi
– volume: 85
  start-page: 413
  year: 2020
  end-page: 423
  ident: bib31
  article-title: MicroRNA-30c-regulated HDAC9 mediates chemoresistance of breast cancer
  publication-title: Canc. Chemother. Pharmacol.
  contributor:
    fullname: Shim
– year: 2019
  ident: 10.1016/j.bbrep.2021.101060_bib10
  article-title: Potential value of circulatory microRNA122 gene expression as a prognostic and metastatic prediction marker for breast cancer
  publication-title: Mol. Biol. Rep.
  doi: 10.1007/s11033-019-04727-5
  contributor:
    fullname: Saleh
– volume: 19
  start-page: 403
  year: 1991
  ident: 10.1016/j.bbrep.2021.101060_bib20
  article-title: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐up
  publication-title: Histopathology
  doi: 10.1111/j.1365-2559.1991.tb00229.x
  contributor:
    fullname: Elston
– volume: 35
  start-page: 1425
  year: 2016
  ident: 10.1016/j.bbrep.2021.101060_bib12
  article-title: MicroRNA-148a inhibits breast cancer migration and invasion by directly targeting WNT-1
  publication-title: Oncol. Rep.
  doi: 10.3892/or.2015.4502
  contributor:
    fullname: Jiang
– volume: 379
  start-page: 432
  year: 2012
  ident: 10.1016/j.bbrep.2021.101060_bib2
  article-title: Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials
  publication-title: Lancet (London, England)
  doi: 10.1016/S0140-6736(11)61625-5
  contributor:
    fullname: Peto
– volume: 7
  start-page: 20381
  year: 2016
  ident: 10.1016/j.bbrep.2021.101060_bib28
  article-title: MiR-148a functions to suppress metastasis and serves as a prognostic indicator in triple-negative breast cancer
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.7953
  contributor:
    fullname: Xu
– start-page: 55
  year: 2017
  ident: 10.1016/j.bbrep.2021.101060_bib7
  contributor:
    fullname: Han
– start-page: 347
  year: 2010
  ident: 10.1016/j.bbrep.2021.101060_bib19
  article-title: Breast
  contributor:
    fullname: Edge
– volume: 4
  start-page: 1393
  year: 2013
  ident: 10.1016/j.bbrep.2021.101060_bib35
  article-title: MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11
  publication-title: Nat. Commun.
  doi: 10.1038/ncomms2393
  contributor:
    fullname: Bockhorn
– volume: 431
  start-page: 350
  year: 2004
  ident: 10.1016/j.bbrep.2021.101060_bib4
  article-title: The functions of animal microRNAs
  publication-title: Nature
  doi: 10.1038/nature02871
  contributor:
    fullname: Ambros
– volume: 9
  start-page: 747
  year: 2020
  ident: 10.1016/j.bbrep.2021.101060_bib32
  article-title: Downregulation of microRNA-30c-5p was responsible for cell migration and tumor metastasis via COTL1-mediated microfilament arrangement in breast cancer
  publication-title: Gland Surg.
  doi: 10.21037/gs-20-472
  contributor:
    fullname: Pei
– volume: 9
  start-page: 402
  year: 2018
  ident: 10.1016/j.bbrep.2021.101060_bib5
  article-title: Overview of MicroRNA biogenesis, mechanisms of actions, and circulation
  publication-title: Front. Endocrinol.
  doi: 10.3389/fendo.2018.00402
  contributor:
    fullname: O'Brien
– volume: 246–247
  start-page: 18
  year: 2020
  ident: 10.1016/j.bbrep.2021.101060_bib8
  article-title: MicroRNAs in breast cancer: new maestros defining the melody
  publication-title: Cancer Genet
  doi: 10.1016/j.cancergen.2020.08.005
  contributor:
    fullname: Khalife
– volume: 259
  year: 2020
  ident: 10.1016/j.bbrep.2021.101060_bib23
  article-title: Role of microRNA in forming breast carcinoma
  publication-title: Life Sci.
  doi: 10.1016/j.lfs.2020.118256
  contributor:
    fullname: Saikia
– volume: 1
  start-page: 1
  year: 2019
  ident: 10.1016/j.bbrep.2021.101060_bib37
  article-title: MicroRNAs and its emerging role as breast cancer diagnostic marker- A review
  publication-title: Adv Biomark Sci Technol
  doi: 10.1016/j.abst.2019.05.001
  contributor:
    fullname: Bhat
– volume: 37
  start-page: 7915
  year: 2016
  ident: 10.1016/j.bbrep.2021.101060_bib39
  article-title: MicroRNA-148a represents an independent prognostic marker in bladder cancer
  publication-title: Tumor Biol.
  doi: 10.1007/s13277-015-4688-0
  contributor:
    fullname: Ma
– volume: 101
  start-page: 2999
  year: 2004
  ident: 10.1016/j.bbrep.2021.101060_bib14
  article-title: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers
  publication-title: Proc. Natl. Acad. Sci. U. S. A.
  doi: 10.1073/pnas.0307323101
  contributor:
    fullname: Calin
– ident: 10.1016/j.bbrep.2021.101060_bib24
  contributor:
    fullname: Turchinovich
– volume: 85
  start-page: 413
  year: 2020
  ident: 10.1016/j.bbrep.2021.101060_bib31
  article-title: MicroRNA-30c-regulated HDAC9 mediates chemoresistance of breast cancer
  publication-title: Canc. Chemother. Pharmacol.
  doi: 10.1007/s00280-019-04024-9
  contributor:
    fullname: Liang
– volume: 486
  start-page: 346
  year: 2012
  ident: 10.1016/j.bbrep.2021.101060_bib21
  article-title: The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
  publication-title: Nature
  doi: 10.1038/nature10983
  contributor:
    fullname: Curtis
– volume: 40
  start-page: 3752
  year: 2018
  ident: 10.1016/j.bbrep.2021.101060_bib17
  article-title: Radioresistant breast cancer cells exhibit increased resistance to chemotherapy and enhanced invasive properties due to cancer stem cells
  publication-title: Oncol. Rep.
  contributor:
    fullname: Ko
– volume: 31
  start-page: 595
  year: 2014
  ident: 10.1016/j.bbrep.2021.101060_bib26
  article-title: Genetics of breast cancer bone metastasis: a sequential multistep pattern
  publication-title: Clin. Exp. Metastasis
  doi: 10.1007/s10585-014-9642-9
  contributor:
    fullname: Fazilaty
– volume: 83
  start-page: 58
  year: 2016
  ident: 10.1016/j.bbrep.2021.101060_bib38
  article-title: Decreased expression of microRNA-148a predicts poor prognosis in ovarian cancer and associates with tumor growth and metastasis
  publication-title: Biomed. Pharmacother.
  doi: 10.1016/j.biopha.2016.05.049
  contributor:
    fullname: Gong
– volume: 37
  start-page: 1581
  year: 2016
  ident: 10.1016/j.bbrep.2021.101060_bib13
  article-title: MicroRNA-148a inhibits migration of breast cancer cells by targeting MMP-13
  publication-title: Tumor Biol.
  doi: 10.1007/s13277-015-3926-9
  contributor:
    fullname: Xue
– volume: 237
  start-page: 474
  year: 2003
  ident: 10.1016/j.bbrep.2021.101060_bib3
  article-title: Rating the risk factors for breast cancer
  publication-title: Ann. Surg.
  doi: 10.1097/01.SLA.0000059969.64262.87
  contributor:
    fullname: Singletary
– ident: 10.1016/j.bbrep.2021.101060_bib6
  contributor:
    fullname: Luo
– volume: 62
  start-page: 15
  year: 2017
  ident: 10.1016/j.bbrep.2021.101060_bib9
  article-title: Recent trends in microRNA research into breast cancer with particular focus on the associations between microRNAs and intrinsic subtypes
  publication-title: J. Hum. Genet.
  doi: 10.1038/jhg.2016.89
  contributor:
    fullname: Kurozumi
– volume: 15
  start-page: 52
  year: 2016
  ident: 10.1016/j.bbrep.2021.101060_bib22
  article-title: ErbB2 and p38γ MAPK mediate alcohol-induced increase in breast cancer stem cells and metastasis
  publication-title: Mol. Canc.
  doi: 10.1186/s12943-016-0532-4
  contributor:
    fullname: Xu
– volume: 36
  year: 2017
  ident: 10.1016/j.bbrep.2021.101060_bib33
  article-title: Collagen triple helix repeat containing-1 negatively regulated by microRNA-30c promotes cell proliferation and metastasis and indicates poor prognosis in breast cancer
  publication-title: J. Exp. Clin. Canc. Res.
  doi: 10.1186/s13046-017-0564-7
  contributor:
    fullname: Lai
– volume: 39
  start-page: 150
  year: 2020
  ident: 10.1016/j.bbrep.2021.101060_bib30
  article-title: MicroRNA-148a-3p inhibits progression of hepatocelluar carcimoma by repressing SMAD2 expression in an Ago2 dependent manner
  publication-title: J. Exp. Clin. Canc. Res.
  doi: 10.1186/s13046-020-01649-0
  contributor:
    fullname: Huang
– volume: 109
  start-page: 1062
  year: 2019
  ident: 10.1016/j.bbrep.2021.101060_bib29
  article-title: Ailanthone exerts anticancer effect by up-regulating miR-148a expression in MDA-MB-231 breast cancer cells and inhibiting proliferation, migration and invasion
  publication-title: Biomed. Pharmacother.
  doi: 10.1016/j.biopha.2018.10.114
  contributor:
    fullname: Gao
– volume: 17
  start-page: 9
  year: 2009
  ident: 10.1016/j.bbrep.2021.101060_bib27
  article-title: Wnt/β-Catenin signaling: components, mechanisms, and diseases
  publication-title: Dev. Cell
  doi: 10.1016/j.devcel.2009.06.016
  contributor:
    fullname: MacDonald
– volume: 25
  start-page: 170
  year: 2011
  ident: 10.1016/j.bbrep.2021.101060_bib15
  article-title: MiR-148a inhibits angiogenesis by targeting ERBB3
  publication-title: J Biomed Res
  doi: 10.1016/S1674-8301(11)60022-5
  contributor:
    fullname: Yu
– volume: 20
  start-page: 4940
  issue: 19
  year: 2019
  ident: 10.1016/j.bbrep.2021.101060_bib11
  article-title: The regulatory role of MicroRNAs in breast cancer
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms20194940
  contributor:
    fullname: Loh
– volume: 9
  start-page: 1106
  year: 2015
  ident: 10.1016/j.bbrep.2021.101060_bib34
  article-title: MicroRNA-30c-2-3p negatively regulates NF-κB signaling and cell cycle progression through downregulation of TRADD and CCNE1 in breast cancer
  publication-title: Mol Oncol
  doi: 10.1016/j.molonc.2015.01.008
  contributor:
    fullname: Shukla
– volume: 71
  start-page: 7
  issue: 1
  year: 2021
  ident: 10.1016/j.bbrep.2021.101060_bib1
  article-title: Cancer Statistics, 2021
  publication-title: Ca - Cancer J. Clin.
  doi: 10.3322/caac.21654
  contributor:
    fullname: Siegel
– volume: 11
  start-page: 2593
  year: 2020
  ident: 10.1016/j.bbrep.2021.101060_bib16
  article-title: Role of MicroRNA-30c in cancer progression
  publication-title: J. Canc.
  doi: 10.7150/jca.38449
  contributor:
    fullname: Han
– volume: 28
  start-page: 588
  year: 2017
  ident: 10.1016/j.bbrep.2021.101060_bib25
  article-title: MicroRNA-148a promotes apoptosis and suppresses growth of breast cancer cells by targeting B-cell lymphoma 2
  publication-title: Anti Canc. Drugs
  doi: 10.1097/CAD.0000000000000498
  contributor:
    fullname: Li
– volume: 127
  start-page: 43
  year: 2011
  ident: 10.1016/j.bbrep.2021.101060_bib18
  article-title: MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer
  publication-title: Breast Canc. Res. Treat.
  doi: 10.1007/s10549-010-0940-x
  contributor:
    fullname: Rodríguez-González
– volume: 17
  start-page: 2964
  year: 2020
  ident: 10.1016/j.bbrep.2021.101060_bib36
  article-title: Application of nanotechnology in cancer diagnosis and therapy - a mini-review
  publication-title: Int. J. Med. Sci.
  doi: 10.7150/ijms.49801
  contributor:
    fullname: Jin
SSID ssj0001528526
Score 2.2494771
Snippet Breast cancer is an extensively identified malignant tumor and is a prime cause of cancer mortalities in females. It has been shown that alteration of miRNAs...
BACKGROUNDBreast cancer is an extensively identified malignant tumor and is a prime cause of cancer mortalities in females. It has been shown that alteration...
• miRNA-148a and miRNA-30c expressions were down regulated in female patients with breast cancer. • Lower levels of miR-148a were associated with lower overall...
Background: Breast cancer is an extensively identified malignant tumor and is a prime cause of cancer mortalities in females. It has been shown that alteration...
SourceID doaj
pubmedcentral
proquest
crossref
pubmed
elsevier
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 101060
SubjectTerms Breast cancer
miRNA-148a
miRNA-30c
SummonAdditionalLinks – databaseName: Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELaqXtoLglJgeVSuxLERiV-xj6Wiqjj0UJWqN8uPWCwS2WqTSvx8Zuyk3QUJLj3GcR7zcGZG-fwNIR9NVGBYZiohkoACJbrKq1ZUxuk6itA0PmS0xaW6-Ca-3srbjVZfiAkr9MBFcZ-C4aLjLUesEZRy0SXvG-YayFSUbFnKX9_abBRTZX8w0zL3WoOIJSupaz1TDmVwl4d6E9kqWYMjdSaofAxLmb1_Kzr9nX3-CaLciErnz8mzKZ2kp0WMF2Sn6w_I3tncxe0lufm5vLo8raAccdT1kZZDXgfa_ZowsP1A3UDvViMCh-BmuCMfQTvrgS576hG1PtKA3rGmEw3rcEiuz79cn11UUy-FKkgmx0qH1iVlYMXBko48sbxrWjkfXJNAfh1qE5gJRnctlGQwj3VRgumSjoEp_ors9qu-e0MoT5wFUztkMhQmNU4yL3hEoyAboVmQk1mT9q4wZtgZSvbDZsVbVLwtil-Qz6jth6lId50HwAns5AT2f06wIGq2lZ0yh5IRwK2W_3768WxZC4bBnyWu71b3g4XCuZVCQTm3IK-LpR_eETnwJDdwdbvlA1tCbJ_pl98zd7fGVvTcvH0Kqd-RfRSlIN7ek91xfd99gBRp9Ed5NfwGoOEKcw
  priority: 102
  providerName: Directory of Open Access Journals
Title miRNA-148a and miRNA-30c expressions as potential biomarkers in breast cancer patients
URI https://dx.doi.org/10.1016/j.bbrep.2021.101060
https://www.ncbi.nlm.nih.gov/pubmed/34195390
https://search.proquest.com/docview/2547546875
https://pubmed.ncbi.nlm.nih.gov/PMC8239439
https://doaj.org/article/c934e3735fc8469dafbb12a11616572f
Volume 27
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELZ2lwNcEG_CozISR7JN_Ep8XCpWKyQKQguquFi2kyxBNK2arMTPZ8aJVy1IHDjGcZyxv0k8k3z-TMhrXSkAlulUiEZAglLZ1KlCpNqWWSV8njsf2BZLdfFFvF_J1RGRcS1MIO171552P9enXfs9cCu3az-PPLH5pw-LEvfz5np-TI7BQfdS9HFpMCslU1FhKHC5HKSXKE7JcizJFO7_hkJmkuO7eG9CCrr9B_PS33Hnn_TJvfno_B65OwWS9Gw0-D45qrsH5PYi7t_2kHxdt5-XZykkIpbarqLjIc88rX9N7Neup7an282AlCFoDNfiI11n19O2ow756gP16Bc7Ogmw9o_I5fm7y8VFOu2ikHrJ5JCWvrCNgq7mMFYVb1hYL62s8zZvYChKn2nPtNdlXUAyBvVYXUkArSkrzxR_TE66TVc_JZQ3nHmdWdQwFLrJrWRO8MrlzKIOoU7ImziSZjtqZZhIIvthAgYGMTAjBgl5i6N9UxWFrkPBZndlJriN11zUvOBINYNMHqxyeL8cAlUlC9YkREWszBQzjLEANNX---6vIrIGgMHfJLarN9e9gZS5kEJBIpeQJyPSNzZGp0lIceADB504PANOHFS7J6d99t9XPid30P6R4PaCnAy76_olRESDm4UvCTNya7lYffw2C8_Db6DLDAQ
link.rule.ids 230,315,730,783,787,867,888,2109,27936,27937,53804,53806
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9QwELVKOZQLonymQDESR9JN_JX4WFatFmhXCC2oN8t2Eghis6tNKvXnM-Mk1S6VOHCM4zi23zieUZ7fEPJOFwqAZToWohIQoBQ2dioTsbZ5Ugifps4HtsVczb6JT1fyao_I8SxMIO17V580v5cnTf0zcCvXSz8ZeWKTL5fTHPN5cz25R-7Dek3EVpDeHw5muWRq1BgKbC4HASbKU7IUSxKFGeBQykxy_BpvbUlBuX9nZ7rref5NoNzakc4fkYeDK0lP-y4fkr2yeUwOpmMGtyfk-7L-Oj-NIRSx1DYF7S954ml5M_Bfm5balq5XHZKGoDE8jY-EnU1L64Y6ZKx31KNlbOggwdo-JYvzs8V0Fg95FGIvmezi3Ge2UjDUFJZzwSsWTkwr67xNK5iK3CfaM-11XmYQjkE9VhYSYKvywjPFn5H9ZtWULwjlFWdeJxZVDIWuUiuZE7xwKbOoRKgj8n6cSbPu1TLMSCP7ZQIGBjEwPQYR-YCzfVsVpa5DwWrzwwyAG6-5KHnGkWwGsTz0yuH7UnBVlcxYFRE1YmUGr6H3BqCp-t9vfzsiawAY_FFim3J13RoImjMpFIRyEXneI33bx9FoIpLt2MDOIHbvgBkH3e7BbI_--8k35GC2uLwwFx_nn1-SBziWnu72iux3m-vyNfhHnTsOq-EPKE4MsA
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELZgkYAL4rmEp5E4km1iO058XArV8qpWaEF7s_yIIYimVZOV-PnMOMmqBYkDxziOY_sbxzPK528Ieam8BGCZSoUIAgIUb1IrS5EqU2VeuDy3LrItlvLki3h_XpzvpPqKpH1nm6P25-qobb5HbuVm5WYTT2x2-mleYT5vrmYbH2ZXyTVYs5ncCdSHA8KsKpicdIYio8tCkIkSlSzHkkxiFjiUMys4fpF3tqWo3r-3O_3tff5JotzZlRa3ya3RnaTHQ7fvkCt1e5fcmE9Z3O6Rr6vm8_I4hXDEUNN6OlzyzNH618iBbTtqOrpZ90gcgsbwRD6SdrYdbVpqkbXeU4fWsaWjDGt3n5wt3p7NT9Ixl0LqClb0aeVKEyQMNYcl7Xlg8dS0NNaZPMBUVC5TjimnqrqEkAzqsdoXAF2ovGOSPyAH7bqtHxLKA2dOZQaVDIUKuSmYFdzbnBlUI1QJeTXNpN4Mihl6opL90BEDjRjoAYOEvMbZvqyKctexYL39pkfQtVNc1LzkSDiDeB56ZfF9ObirsihZSIicsNKj5zB4BNBU8--3v5iQ1QAM_iwxbb2-6DQEzmUhJIRzCTkckL7s42Q0CSn3bGBvEPt3wJSjdvdouo_--8nn5Prpm4X--G754TG5iUMZGG9PyEG_vaifgovU22dxMfwGCBYNww
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=miRNA-148a+and+miRNA-30c+expressions+as+potential+biomarkers+in+breast+cancer+patients&rft.jtitle=Biochemistry+and+biophysics+reports&rft.au=Elhelbawy%2C+Nesreen+G.&rft.au=Zaid%2C+Ibrahim+F.&rft.au=Khalifa%2C+Aya+A.&rft.au=Gohar%2C+Suzy+F.&rft.date=2021-09-01&rft.pub=Elsevier&rft.eissn=2405-5808&rft.volume=27&rft_id=info:doi/10.1016%2Fj.bbrep.2021.101060&rft_id=info%3Apmid%2F34195390&rft.externalDBID=PMC8239439
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2405-5808&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2405-5808&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2405-5808&client=summon